BRAF and melanoma: Since treatment with chemotherapeutics is still the most common primary therapy in the majority of the world and generally indicated if the tumour shows insensitivity against targeted strategies such as BRAF inhibition47, our findings are particularly important and show the relevance of molecular melanoma characterisation prior to therapy in order to exclude cross-resistance effects and improve patient outcome48.